Exclusive-Germany may miss COVID-19 vaccine donation goal, blames manufacturers
Reuters
Published Oct 19, 2021 15:21
Updated Oct 20, 2021 08:05
BERLIN (Reuters) -Germany may miss its target to donate 100 million COVID-19 vaccine doses this year due to conditions imposed by manufacturers and delivery shortfalls, a health ministry official said in a letter to Brussels seen by Reuters.
The 100 million doses account for half the total promised by European Union member states to poorer countries this year, according to the European Commission.
The German foreign office said on Oct. 19 that Germany had only donated just over 17% of that amount.
In a letter on Monday to the European Commission's Health Emergency Preparedness and Response Authority (HERA), health ministry state secretary Thomas Steffen said there were "ongoing bureaucratic, logistical and legal problems" imposed by vaccine makers on EU countries wanting to donate surplus shots.
Steffen said these factors made "a quick response to international requests for help almost impossible."
The letter is the strongest sign yet of the tensions between governments and drugmakers over donations.
The EU and rich countries, most of whose most vulnerable citizens have been vaccinated, are under pressure from the World Health Organization to deliver more doses to poorer nations, many of which have inoculated only a fraction of their people.
"With vaccine surpluses in many member states increasing at present, we will soon be facing a situation of global allocation emergency," Steffen wrote. "Some countries could be forced to waste large volumes of valuable vaccines urgently needed in other parts of the world."
He said obstacles included minimum sales prices, onerous compensation payments required of recipient countries and restrictions on distributing to international organisations.
Changes in expected delivery volumes and expiration dates of vaccine doses also made planning more difficult, he added.
Steffen said AstraZeneca (NASDAQ:AZN) and Johnson & Johnson (NYSE:JNJ) could together only deliver up to 50 million doses of their COVID-19 vaccines this year, meaning Germany would also have to donate Pfizer/BioNTech and Moderna (NASDAQ:MRNA) shots that are the mainstays of its vaccination drive.
In response, Johnson & Johnson said it would help countries with surplus doses to donate them to other countries, especially using the international COVAX facility, as long as the countries met safety, legal, regulatory and logistical requirements.
AstraZeneca said it was supporting donations in addition to regular supply agreements with individual countries and COVAX, and said it had helped with about 85% of all donations in Germany so far.
"The donation of vaccines is a complex administrative process with long lead times that are outside vaccine manufacturers' control," it added.
Get The App
Other manufacturers could not immediately be reached for comment.
EU countries have mostly promised to donate AstraZeneca and Johnson & Johnson vaccines. Many have restricted the use of these vaccines due to very rare cases of blood clotting.
Any shortfall in donations is likely to heighten criticism of richer nations, which are rolling out boosters and inoculating teenagers considered a low-risk from COVID-19, while the pandemic rages elsewhere.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.